Primobolan 150 Methenolone Enanthate

• Category: Injectable Anabolic-Androgenic Steroid (Research Only)
• Brand: Royal Pharmaceuticals
• Strength: 150 mg methenolone enanthate per ml
• Packaging: 10 1 ml ampoules (oil-based I.M. solution)
• Origin: United Kingdom
• Use Notice: Research/analytical use only — not for human or veterinary administration.

What is Methenolone Enanthate?

Methenolone enanthate (Primobolan) is a dihydrotestosterone (DHT)-derived anabolic steroid characterised by:

• Negligible aromatisation — does not convert to estrogen
• Lower androgenic index compared with testosterone
• Long-acting enanthate ester that extends release after I.M. injection
• Stable anabolic profile often evaluated in nitrogen-balance and lean-mass preservation models

In research contexts, methenolone is studied for its potential to preserve muscle mass, reduce catabolism and support erythropoiesis with fewer estrogen-mediated variables.

Key Compound Details

• Chemical name: 1-methyl-5-androst-1-en-17-ol-3-one enanthate
• Parent structure: DHT (non-aromatising)
• Pharmacological class: Esterified anabolic-androgenic steroid
• Route: Intramuscular depot
• Androgenic activity: Lower than testosterone in scaled comparisons
• Ester effect: Several-day release profile; prolonged exposure window

Mechanism of Action

After injection, the enanthate ester is slowly cleaved, releasing free methenolone which:

• Binds androgen receptors (AR) in skeletal muscle and other tissues
• Modulates transcription of androgen-responsive genes
• Promotes structural protein synthesis and nitrogen retention
• Shows reduced catabolic signalling in some research models
• Does not increase estrogenic activity, avoiding aromatase-mediated effects

These characteristics make methenolone valuable for experiments where stable anabolic action is required without confounding estrogenic variables.

Research Highlights & Observations

• Lean mass preservation in catabolic states when nutrition is adequate
• Mild erythropoietic effect — increases RBC and hemoglobin in some studies
• Lower fluid retention compared with aromatising androgens
• Relatively favourable tolerability profile in historical clinical literature

These findings apply to controlled laboratory or clinical research settings only.

• Safety Profile & Possible Adverse Effects
• (Based on class-wide AAS research data.)
• Androgenic

• Acne, oily skin, increased body/facial hair
• Potential DHT-related scalp hair loss
• Virilisation in females (voice deepening, menstrual disruption)

Cardiovascular & Metabolic

• Reduced HDL, possible increase in LDL
• Blood pressure changes
• Elevated hematocrit via RBC stimulation

Endocrine

• Suppression of LH/FSH
• Reduced endogenous testosterone
• Impaired spermatogenesis and fertility

Hepatic

Lower hepatotoxicity than 17-alkylated orals, but liver enzymes may still elevate

Other

• Injection-site irritation
• Mood or behavioural changes
• Potential interactions with anticoagulants or metabolic drugs

Compliance & Regulatory Notice

Methenolone and its esters are prohibited anabolic agents under WADA (S1).

Controlled substance in many jurisdictions; distribution/use may require licensing.

This product is sold strictly for laboratory and analytical research only.

No medical claims, dosing guidance or human-use recommendations are provided.

Technical Data Table

For laboratory and analytical research only — not for human or veterinary use.